PCVX Vaxcyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCVX

Price (delayed)

$37.58

Market cap

$3.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.44

Enterprise value

$2.19B

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious ...

Highlights
PCVX's quick ratio has surged by 168% year-on-year and by 150% since the previous quarter
Vaxcyte's equity has surged by 165% QoQ
The debt has declined by 9% since the previous quarter but it is up by 7% year-on-year
The net income has plunged by 123% YoY and by 28% from the previous quarter
The EPS has plunged by 78% YoY and by 17% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://vaxcyte.com/
Peers: OVID

Key stats

What are the main financial stats of PCVX
Market
Shares outstanding
80.03M
Market cap
$3.01B
Enterprise value
$2.19B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$223.48M
EBITDA
-$214.29M
Free cash flow
-$176.44M
Per share
EPS
-$3.44
Free cash flow per share
-$2.72
Book value per share
$12.07
Revenue per share
$0
TBVPS
$15.51
Balance sheet
Total assets
$1.01B
Total liabilities
$52.57M
Debt
$17.94M
Equity
$953.61M
Working capital
$902.03M
Liquidity
Debt to equity
0.02
Current ratio
23.26
Quick ratio
22.98
Net debt/EBITDA
3.81
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-40%
Return on equity
-43.8%
Return on invested capital
-143.4%
Return on capital employed
-23.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCVX stock price

How has the Vaxcyte stock price performed over time
Intraday
-0.92%
1 week
-3.39%
1 month
-12.6%
1 year
48.77%
YTD
-21.63%
QTD
-21.63%

Financial performance

How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$232.26M
Net income
-$223.49M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has shrunk by 124% YoY and by 32% QoQ
The net income has plunged by 123% YoY and by 28% from the previous quarter

Growth

What is Vaxcyte's growth rate over time

Valuation

What is Vaxcyte stock price valuation
P/E
N/A
P/B
3.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 78% YoY and by 17% from the previous quarter
Vaxcyte's equity has surged by 165% QoQ
The P/B is 17% lower than the last 4 quarters average of 3.8

Efficiency

How efficient is Vaxcyte business performance
PCVX's ROIC has dropped by 164% year-on-year and by 48% since the previous quarter
PCVX's ROA is down by 42% YoY but it is up by 11% QoQ
Vaxcyte's return on equity has decreased by 35% YoY but it has increased by 14% QoQ

Dividends

What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCVX.

Financial health

How did Vaxcyte financials performed over time
PCVX's quick ratio has surged by 168% year-on-year and by 150% since the previous quarter
Vaxcyte's current ratio has surged by 160% YoY and by 147% QoQ
The debt is 98% smaller than the equity
Vaxcyte's equity has surged by 165% QoQ
The company's debt to equity has shrunk by 67% QoQ and by 67% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.